| Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia JH Kersey, D Weisdorf, ME Nesbit, TW LeBien, WG Woods, PB McGlave, ... New England Journal of Medicine 317 (8), 461-467, 1987 | 425 | 1987 |
| IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced … DA Vallera, M Felices, R McElmurry, V McCullar, X Zhou, JU Schmohl, ... Clinical Cancer Research 22 (14), 3440-3450, 2016 | 357 | 2016 |
| In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice BR Blazar, PA Taylor, PS Linsley, DA Vallera | 313 | 1994 |
| Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia Q Zhou, ME Munger, SL Highfill, J Tolar, BJ Weigel, M Riddle, AH Sharpe, ... Blood, The Journal of the American Society of Hematology 116 (14), 2484-2493, 2010 | 309 | 2010 |
| CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets MK Gleason, JA Ross, ED Warlick, TC Lund, MR Verneris, A Wiernik, ... Blood, The Journal of the American Society of Hematology 123 (19), 3016-3026, 2014 | 277 | 2014 |
| Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. WJ Murphy, LA Welniak, DD Taub, RH Wiltrout, PA Taylor, DA Vallera, ... The Journal of clinical investigation 102 (9), 1742-1748, 1998 | 277 | 1998 |
| Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition A Wiernik, B Foley, B Zhang, MR Verneris, E Warlick, MK Gleason, ... Clinical cancer research 19 (14), 3844-3855, 2013 | 250 | 2013 |
| Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production MK Gleason, MR Verneris, DA Todhunter, B Zhang, V McCullar, SX Zhou, ... Molecular cancer therapeutics 11 (12), 2674-2684, 2012 | 247 | 2012 |
| Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. BR Blazar, PA Taylor, A Panoskaltsis-Mortari, J Buhlman, J Xu, RA Flavell, ... Journal of Immunology (Baltimore, Md.: 1950) 158 (1), 29-39, 1997 | 232 | 1997 |
| 3D bioprinted in vitro metastatic models via reconstruction of tumor microenvironments F Meng, CM Meyer, D Joung, DA Vallera, MC McAlpine, ... Advanced Materials 31 (10), 1806899, 2019 | 228 | 2019 |
| Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease AH Filipovich, RJ Youle, DM Neville Jr, DA Vallera, RR Quinones, ... The Lancet 323 (8375), 469-472, 1984 | 214 | 1984 |
| Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies DA Vallera, RC Ash, ED Zanjani, JH Kersey, TW LeBien, PCL Beverley, ... Science 222 (4623), 512-515, 1983 | 187 | 1983 |
| Bone marrow transplantation across major histocompatibility barriers in mice Effect of elimination of T cells from donor grafts by treatment with monoclonal Thy-1.2 plus … DA Vallera, CCB Soderling, GJ Carlson, JH Kersey Transplantation 31 (3), 218-222, 1981 | 180 | 1981 |
| Infusion of anti-B7. 1 (CD80) and anti-B7. 2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells. BR Blazar, AH Sharpe, PA Taylor, A Panoskaltsis-Mortari, GS Gray, ... Journal of immunology (Baltimore, Md.: 1950) 157 (8), 3250-3259, 1996 | 177 | 1996 |
| Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia Q Zhou, C Bucher, ME Munger, SL Highfill, J Tolar, DH Munn, BL Levine, ... Blood, The Journal of the American Society of Hematology 114 (18), 3793-3802, 2009 | 173 | 2009 |
| Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells M Felices, TR Lenvik, ZB Davis, JS Miller, DA Vallera Natural Killer Cells: Methods and Protocols, 333-346, 2016 | 162 | 2016 |
| Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice A Panoskaltsis-Mortari, DL Lacey, DA Vallera, BR Blazar Blood, The Journal of the American Society of Hematology 92 (10), 3960-3967, 1998 | 161 | 1998 |
| Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts BR Blazar, PA Taylor, S Smith, DA Vallera | 159 | 1995 |
| Coblockade of the LFA1: ICAM and CD28/CTLA4: B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major … BR Blazar, PA Taylor, A Panoskaltsis-Mortari, GS Gray, DA Vallera | 157 | 1995 |
| Rapamycin inhibits the generation of graft-versus-host disease-and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines BR Blazar, PA Taylor, A Panoskaltsis-Mortari, DA Vallera The Journal of Immunology 160 (11), 5355-5365, 1998 | 154 | 1998 |
